Abstract
Serine Protease Inhibitor Kazal type 1 (SPINK1) protects against premature intracellular activation of trypsinogen and development of acute pancreatitis. Our aim was to determine the prevalence of SPINK1 mutations (a) in unselected patients with first-time acute pancreatitis and (b) in the Danish background population (c) in a meta-analysis to combine the results with findings in similar investigations worldwide and (d) to evaluate whether patients with SPINK1 mutations had a more severe clinical course.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | European Journal of Gastroenterology and Hepatology |
| Vol/bind | 24 |
| Udgave nummer | 3 |
| Sider (fra-til) | 309-15 |
| Antal sider | 7 |
| ISSN | 0954-691X |
| DOI | |
| Status | Udgivet - 2012 |
Bibliografisk note
Author(s): Joergensen, MT (Joergensen, Maiken Thyregod)[ 1 ] ; Brusgaard, K (Brusgaard, Klaus)[ 2 ] ; Novovic, S (Novovic, Srdan)[ 4 ] ; Andersen, AM (Andersen, Anders Moller)[ 4 ] ; Hansen, MB (Hansen, Mark Berner)[ 4,5 ] ; Gerdes, AM (Gerdes, Anne-Marie)[ 2,3 ] ; de Muckadell, OBS (de Muckadell, Ove Bent Schaffalitzky)[ 1 ]1 ] Univ So Denmark, Dept Med Gastroenterol S, Odense Univ Hosp, DK-5000 Odense C, Denmark
[ 2 ] Univ So Denmark, Dept Clin Genet, Odense Univ Hosp, DK-5000 Odense C, Denmark
[ 3 ] Univ Copenhagen, Rigshosp, Dept Clin Genet, DK-2100 Copenhagen, Denmark
[ 4 ] Univ Copenhagen, Bispebjerg Hosp, Dept Surg K, Copenhagen, Denmark
[ 5 ] AstraZeneca Res & Dev, Molndal, Sweden